Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Nolan Williams, Boris D. Heifets, Christine Blasey, et al.
American Journal of Psychiatry (2018) Vol. 175, Iss. 12, pp. 1205-1215
Open Access | Times Cited: 418

Showing 1-25 of 418 citing articles:

Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation
Roger S. McIntyre, Joshua D. Rosenblat, Charles B. Nemeroff, et al.
American Journal of Psychiatry (2021) Vol. 178, Iss. 5, pp. 383-399
Open Access | Times Cited: 487
Psychedelics and Psychedelic-Assisted Psychotherapy
Collin Reiff, Elon E. Richman, Charles B. Nemeroff, et al.
American Journal of Psychiatry (2020) Vol. 177, Iss. 5, pp. 391-410
Closed Access | Times Cited: 462
The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders
Gin S. Malhi, Erica Bell, Darryl Bassett, et al.
Australian & New Zealand Journal of Psychiatry (2020) Vol. 55, Iss. 1, pp. 7-117
Closed Access | Times Cited: 395
Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis
Anees Bahji, Gustavo Vázquez, Carlos A. Zarate
Journal of Affective Disorders (2020) Vol. 278, pp. 542-555
Open Access | Times Cited: 300
Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective
Kenji Hashimoto
Psychiatry and Clinical Neurosciences (2019) Vol. 73, Iss. 10, pp. 613-627
Open Access | Times Cited: 287
Blinding and expectancy confounds in psychedelic randomized controlled trials
Suresh Muthukumaraswamy, Anna Forsyth, Thomas Lumley
Expert Review of Clinical Pharmacology (2021) Vol. 14, Iss. 9, pp. 1133-1152
Closed Access | Times Cited: 215
Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability
Jordi Bonaventura, Sherry Lam, Meghan L. Carlton, et al.
Molecular Psychiatry (2021) Vol. 26, Iss. 11, pp. 6704-6722
Open Access | Times Cited: 210
Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine
Danilo De Gregorio, Argel Aguilar‐Valles, Katrin H. Preller, et al.
Journal of Neuroscience (2020) Vol. 41, Iss. 5, pp. 891-900
Open Access | Times Cited: 188
<p>Ketamine and depression: a narrative review</p>
Alexandrine Corriger, Gisèle Pickering
Drug Design Development and Therapy (2019) Vol. Volume 13, pp. 3051-3067
Open Access | Times Cited: 184
Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics
Lily R. Aleksandrova, Anthony G. Phillips
Trends in Pharmacological Sciences (2021) Vol. 42, Iss. 11, pp. 929-942
Closed Access | Times Cited: 167
Ketamine: A tale of two enantiomers
Luke A. Jelen, Allan H. Young, James Stone
Journal of Psychopharmacology (2020) Vol. 35, Iss. 2, pp. 109-123
Open Access | Times Cited: 166
Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites
Chun Yang, Jianjun Yang, Ailin Luo, et al.
Translational Psychiatry (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 164
Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers
Dmitriy Matveychuk, Rejish K. Thomas, Jennifer Swainson, et al.
Therapeutic Advances in Psychopharmacology (2020) Vol. 10
Open Access | Times Cited: 164
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Antonio Inserra, Danilo De Gregorio, Gabriella Gobbi
Pharmacological Reviews (2020) Vol. 73, Iss. 1, pp. 202-277
Open Access | Times Cited: 163
Monoaminergic system and depression
Laura Pérez-Caballero, Sonia Torres-Sánchez, Cristina Romero-López-Alberca, et al.
Cell and Tissue Research (2019) Vol. 377, Iss. 1, pp. 107-113
Closed Access | Times Cited: 158
The cellular and molecular basis of major depressive disorder: towards a unified model for understanding clinical depression
Eleni Pitsillou, Sarah M. Bresnehan, Evan A. Kagarakis, et al.
Molecular Biology Reports (2019) Vol. 47, Iss. 1, pp. 753-770
Closed Access | Times Cited: 158
Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials
Jacob S. Aday, Boris D. Heifets, Steven D. Pratscher, et al.
Psychopharmacology (2022) Vol. 239, Iss. 6, pp. 1989-2010
Open Access | Times Cited: 149
Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy
Jennifer Dore, Brent Turnipseed, Shannon Dwyer, et al.
Journal of Psychoactive Drugs (2019) Vol. 51, Iss. 2, pp. 189-198
Open Access | Times Cited: 147
A Brain-Centric Model of Suicidal Behavior
J. John Mann, Mina Rizk
American Journal of Psychiatry (2020) Vol. 177, Iss. 10, pp. 902-916
Open Access | Times Cited: 144
Prescription Opioid Use and Risk for Major Depressive Disorder and Anxiety and Stress-Related Disorders
Daniel B. Rosoff, George Davey Smith, Falk W. Lohoff
JAMA Psychiatry (2020) Vol. 78, Iss. 2, pp. 151-151
Open Access | Times Cited: 141
A historical review of antidepressant effects of ketamine and its enantiomers
Wei Yan, Lijia Chang, Kenji Hashimoto
Pharmacology Biochemistry and Behavior (2020) Vol. 190, pp. 172870-172870
Open Access | Times Cited: 140
Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial
Mocrane Abbar, Christophe Dematteï, Wissam El‐Hage, et al.
BMJ (2022), pp. e067194-e067194
Open Access | Times Cited: 119
Mechanisms of ketamine and its metabolites as antidepressants
Evan Hess, Lace M. Riggs, Michael Michaelides, et al.
Biochemical Pharmacology (2021) Vol. 197, pp. 114892-114892
Open Access | Times Cited: 117
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
Ioline D. Henter, Lawrence T. Park, Carlos A. Zarate
CNS Drugs (2021) Vol. 35, Iss. 5, pp. 527-543
Open Access | Times Cited: 112
Treatment of Posttraumatic Stress Disorder: A State-of-the-art Review
Lisa Burback, Suzette Brémault‐Phillips, Mirjam J. Nijdam, et al.
Current Neuropharmacology (2023) Vol. 22, Iss. 4, pp. 557-635
Closed Access | Times Cited: 96
Page 1 - Next Page

Scroll to top